Cardarine (GW-501516)
PPARδ agonist; metabolic and endurance research (non-SARM)
Mechanism of Action
Cardarine (GW-501516) is a selective PPARδ (peroxisome proliferator-activated receptor delta) agonist. Despite commonly being grouped with SARMs, it is not an androgen receptor ligand. PPARδ activation enhances fatty acid oxidation, mitochondrial biogenesis, and metabolic efficiency in skeletal muscle. In preclinical models, GW-501516 dramatically increased running endurance (type I muscle fiber transformation) and improved metabolic markers. Clinical development was halted after Phase II due to concerns about potential carcinogenicity in animal models, though the clinical relevance remains debated. Studied for metabolic syndrome, exercise performance, and lipid modulation.
Evidence Chain
Cardarine (GW-501516)
COMPOUND
2 Research Goals
• Weight Management
• Anti-Aging & Longevity
Evidence Strength
6 articles sourced
Knowledge Graph
(8 connections)Research Goals
(2)Research Evidence
(6)Enobosarm (Ostarine / MK-2866): Evidence-Based Research Review
**Class:** SARM (Selective Androgen Receptor Modulator)
Cardarine vs Ostarine: Evidence-Based Comparison
Cardarine (GW-501516) and Ostarine (MK-2866/Enobosarm) are two distinct chemical compounds frequently discussed in the contexts of metabolic research, sports science, and clinical muscle wasting. While they are often marketed together in the "SARM" (Selective Androgen Receptor Modulator) category, t
YK-11: Evidence-Based Research Review
YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal
Testolone (RAD-140): Evidence-Based Research Review
Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.
Cardarine (GW-501516): Evidence-Based Research Review
Cardarine (GW-501516) is a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist originally developed through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline (GSK) for the treatment of metabolic and cardiovascular diseases. Although frequently categorized as a
Andarine (S-4): Evidence-Based Research Review
Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
Cardarine (GW-501516) + Atorvastatin
High Compatibility
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.